沙格列汀在肾功能不全2型糖尿病的有效性.pptx

Saxagliptin;Objectives:;Objectives:;Study Design;Selected Inclusion and Exclusion Criteria;Subject Disposition:;Demographic and Baseline Characteristics: Randomized Analysis Set;Baseline Diabetes Characteristics: Randomized Analysis Set;;;;HbA1c Change From Baseline to Week 52: LOCF, Full Analysis Set (2 of 2);Reference: Table 7.2.2bLT; Figure 7.2LT;Mean Change From Baseline HbA1c: LOCF, Full Analysis Set;FPG Change From Baseline to Week 52 by Renal Impairment Category: LOCF, Full Analysis Set (3 of 3);Summary of Efficacy Results:;Change in Antihyperglycemic Medications: ST + LT Period;Overall Summary of Adverse Events: Safety Analysis Set ;Most Common Adverse Events (?2%) by SOC;Summary of Deaths: Safety Analysis Set;SAEs (?2%) by SOC and Preferred Term: Safety Analysis Set;Summary of Hypoglycemic Events;Summary of Adverse Events of Interest During ST + LT Period: Safety Analysis Set;Changes From Baseline in Serum Creatinine in Subjects With Moderate or Severe Renal Impairment: Safety Analysis Set;Change From Baseline in Body Weight, BMI, and Waist Circumference: LOCF, Safety Analysis Set;Summary of Safety Results: ST + LT Period (1 of 2);Summary of Safety Results: ST + LT Period (2 of 2);Overall Study Conclusions (1 of 2);Overall Study Conclusions (2 of 2);Back Up;HbA1c Change From Baseline to Week 52 by Renal Impairment Category: LOCF, Full Analysis Set (1 of 3);HbA1c Change From Baseline to Week 52 by Renal Impairment Category: LOCF, Full Analysis Set (2 of 3);FPG Change From Baseline to Week 52 by Renal Impairment Category: LOCF, Full Analysis Set (1 of 3);FPG Change From Baseline to Week 52 by Renal Impairment Category: LOCF, Full Analysis Set (2 of 3);Most Common AEs (?2%) by SOC and Preferred Term: Safety Analysis Set (1 of 3);Most Common AEs (?2%) by SOC and Preferred Term: Safety Analysis Set (2 of 3);Most Common AEs (?2%) by SOC and Preferred Term: Safety Analysis Set (3 of 3);Changes From Baseline in CrCl in Subjects With Moderate or Severe Renal